References

10.1016/j.bbalip.2008.06.002

10.1016/j.bbalip.2008.06.002 · External reference

Alkaline ceramidase family: The first two decades

10.1016/j.cellsig.2020.109860 · 2021 · External reference

10.1074/jbc.270.19.11098

10.1074/jbc.270.19.11098 · External reference

10.1074/jbc.m303310200

10.1074/jbc.m303310200 · External reference

10.1016/j.str.2015.06.013

10.1016/j.str.2015.06.013 · External reference

10.1074/jbc.m303875200

10.1074/jbc.m303875200 · External reference

10.1074/jbc.m109.069203

10.1074/jbc.m109.069203 · External reference

10.1074/jbc.m109.063586

10.1074/jbc.m109.063586 · External reference

ASAH1 facilitates TNBC by DUSP5 suppression-driven activation of MAP kinase pathway and represents a therapeutic vulnerability

10.1038/s41419-024-06831-2 · 2024 · External reference

Carmofur prevents cell cycle progression by reducing E2F8 transcription in temozolomide-resistant glioblastoma cells

10.1038/s41420-023-01738-x · 2023 · External reference

Acid ceramidase controls proteasome inhibitor resistance and is a novel therapeutic target for the treatment of relapsed/refractory multiple myeloma

2025 · External reference

10.1038/mt.2008.281

10.1038/mt.2008.281 · External reference

10.1038/srep01035

10.1038/srep01035 · External reference

10.4049/jimmunol.2000500

10.4049/jimmunol.2000500 · External reference

Neutral ceramidase regulates breast cancer progression by metabolic programming of TREM2-associated macrophages

10.1038/s41467-024-45084-7 · 2024 · External reference

Tumor suppressor ACER1 correlates with prognosis and Immune Infiltration in head and neck squamous cell carcinoma

10.1038/s41598-024-78663-1 · 2024 · External reference

10.1016/j.prp.2018.07.029

10.1016/j.prp.2018.07.029 · External reference

10.1016/j.bbrc.2016.07.099

10.1016/j.bbrc.2016.07.099 · External reference

Alkaline ceramidase 2 is a novel direct target of p53 and induces autophagy and apoptosis through ROS generation

10.1038/srep44573 · 2017 · External reference

Tumor suppressor p53 links ceramide metabolism to DNA damage response through alkaline ceramidase 2

2018 · External reference

Targeting YTHDF2 inhibits tumorigenesis of diffuse large B-cell lymphoma through ACER2-mediated ceramide catabolism

10.1016/j.jare.2023.10.010 · 2024 · External reference

10.1111/cas.14453

10.1111/cas.14453 · External reference

Osteoblast-derived exosomal miR-140-3p targets ACER2 and increases the progression of prostate cancer via the AKT/mTOR pathway-mediated inhibition of autophagy

10.1096/fj.202401480r · 2024 · External reference

Contribution of sphingomyelin phosphodiesterase acid-like 3B to the proliferation, migration, and invasion of ovarian cancer cells

10.21037/tcr-24-309 · 2024 · External reference

ACER2 forms a cold tumor microenvironment and predicts the molecular subtype in bladder cancer: Results from real-world cohorts

10.3389/fgene.2023.1148437 · 2023 · External reference

10.1038/s41419-020-03106-4

10.1038/s41419-020-03106-4 · External reference

10.1074/jbc.m110.105296

10.1074/jbc.m110.105296 · External reference

10.1016/j.chemphyslip.2015.07.009

10.1016/j.chemphyslip.2015.07.009 · External reference

Potent inhibition of Acid ceramidase by novel B-13 analogues

2011 · External reference

Novel amide– and sulfonamide-based aromatic ethanolamines: effects of various substituents on the inhibition of acid and neutral ceramidases

10.1016/j.bmc.2012.08.031 · 2012 · External reference

10.1074/jbc.271.21.12646

10.1074/jbc.271.21.12646 · External reference

10.1002/anie.202109967

10.1002/anie.202109967 · External reference

10.1002/jcc.21334

10.1002/jcc.21334 · External reference

10.1096/fj.09-153635

10.1096/fj.09-153635 · External reference

Alkaline ceramidase 2 and its bioactive product sphingosine are novel regulators of the DNA damage response

10.18632/oncotarget.7825 · 2016 · External reference

PKCα is required for Akt-mTORC1 activation in non-small cell lung carcinoma (NSCLC) with EGFR mutation

10.1038/s41388-019-0950-z · 2019 · External reference